Decreases in Paraoxonase-1 Activities Promote a Pro-inflammatory Effect of Lipids Peroxidation Products in Non-smoking and Smoking Patients with Acute Pancreatitis

Grzegorz Marek1, Milena Ściskalska2, Zygmunt Grzebieniak1, Halina Milnerowicz2

1. Second Department of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland.  
2. Department of Biomedical and Environmental Analyses, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.

Abstract

**Aim:** The study investigated the extent to which tobacco smoke exposure causes changes in lipids biochemistry through measurement blood concentrations of: paraoxonase-1 (PON-1) activities as lipid-bound enzyme into cell membrane, concentration of malonyldialdehyde (MDA), protein adducts of 4-hydroxynonenal (HNE-adducts), oxidized low density lipoproteins (oxLDL), total cholesterol (CH) and high-density lipoprotein cholesterol (HDL). Additionally, the activity of P isoform of glutathione S-transferase (GST-π) was measured.

**Methods:** Investigations were performed in the blood of patients with acute pancreatitis (AP) on the 1st, 3rd and 7th day of hospitalization and in healthy volunteers. The activities of PON-1 forms, GST-π were determined spectrophotometrically. Concentrations of PON-1, MDA, HNE-adducts, oxLDL, HDL, CH were measured using commercial tests.

**Results:** Near 2-fold higher concentrations of MDA, HNE-adducts, oxLDL, correlating with inflammatory markers in AP patients compared to healthy subjects were demonstrated, which were accompanied by gradually increasing CH/HDL ratio during hospitalization. During hospital treatment, decreased activities of all PON-1 subtypes were observed in AP patients compared to healthy subjects, more pronounced in tobacco smokers. A decreased PON-1 phosphotriesterase activity in non-AP control group smokers compared to non-smokers was noted. In non-smoking AP patients GST-π activity normalized during hospitalization in contrast to smokers.

**Conclusions:** GST-π and PON-1 phosphotriesterase activities seem to be a sensitive marker of pro/antioxidative imbalance in smokers. Lipids peroxidation products generated during AP can intensify preexisting inflammation. Increasing stay in the hospital was associated with worsening of lipids peroxidation markers and the parameters of lipid profile, in both non-smoking and smoking AP patients, what can indicate that the oxidative-inflammatory process are not extinguished.

Key words: acute pancreatitis; GST-π; malonyldialdehyde; paraoxonase-1; smoking.

Introduction

Acute pancreatitis (AP) is one of major causes of hospital admissions for gastrointestinal diseases in many countries. The molecular and biochemical pathomechanism of AP has not been fully understood [1]. It is believed that the primary mechanism of pathogenesis of acute pancreatitis lies in
intracellular activation of proenzymes in the exocrine cells of the pancreas, which subsequently results in disruption of the compartmentalization of alveolar cells and self-digestion of the organ [2]. There is also an important role played in the activation of pancreatic enzymes by Ca\(^{2+}\) ions. Destruction of pancreatic acinar cells activates chemotaxis of leukocytes and macrophages, which leads to local and subsequent to systemic inflammatory response [3–5]. Acute inflammation of the pancreatic tissue results in a clinical spectrum ranging from mild and self-limiting to severe, progressing disease associated with high risk of mortality [6].

Tobacco smoke exposure is one of many major factors in the pathogenesis of inflammatory diseases, including acute pancreatitis and was associated with worse AP course [6,7]. Recent evidence has indicated that smoking can be considered as an independent risk factor for AP [6]. Tobacco smoke is a composite mixture of different substances with toxic potential (with prooxidative, proinflammatory, carcinogenic, mutagenic and teratogenic effect) on human cells [8,9]. Xenobiotics and free radicals from the smoke are responsible for activation of pro-inflammatory pathways leading to the release of inflammatory mediators [8,10].

The first line of cellular defense against free radicals is cell membrane. Free radicals produced as a result of tobacco smoke exposure can interact with molecules incorporated within cellular membrane. Oxidative damage to the membrane phospholipids initiates lipid peroxidation [11,12]. This process generates a variety of α- and β-unsaturated reactive aldehydes, among others malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). It contributes to oxidative modification of physiological molecules, such as low density lipoproteins (LDL) turning them into oxidized form – oxLDLs. Products of lipid peroxidation may in turn lead to damage of membrane integrity, inactivation of membrane-bound receptors and enzymes, resulting in cell damage [13]. These lipid peroxidation products, especially 4-HNE, react with proteins, changing their conformation and function, leading to enhanced inflammatory response [14].

Peroxidation of lipids can be limited by the activity of paraoxonase-1 (PON-1) [15–17]. PON-1 is a HDL-bound and calcium-dependent extracellular hydrolase [18–21], produced in the liver and secreted into the bloodstream [11]. This enzyme has the ability to delay or inhibit the initiation of lipoproteins oxidation induced by metal ions and to hydrolyse preformed lipid hydroperoxides [20,21]. The hydrolytic activity of PON-1 on different substrates occurs in three types of enzymatic action: as phosphotriesterase (paraoxonase) (EC 3.1.8.1), as ariesterase (EC 3.1.1.2) and as lactonase (EC 3.1.1.81) [22]. PON-1 was observed as an important endogenous free radical scavenging system in the human body [23]. The activity of this enzyme was shown to be modulated under oxidative stress conditions, such as exposure to tobacco smoke xenobiotics [18]. It was also recognized as an agent modulating antioxidative and anti-inflammatory role of HDL [19–21]. Due to its potential ability to hydrolyse proinflammatory mediator-platelet-activating factor (PAF), PON-1 may exert anti-inflammatory effects [15,24].

Enhanced oxidative stress through inflammation and/or cigarette smoking exposure usually activates intracellular antioxidant defenses as an adaptive response to free radicals action. Important enzymes, which take part in antioxidative defense are glutathione S transferases (GST, EC 2.5.1.18), including Π isoform of GST (GST-π). GST-π is responsible for detoxification of tobacco smoke constituents and protection against smoking-induced oxidative damage [25]. It is a typical isozyme in erythrocytes, for which a role in Cd accumulation as a major constituent of the smoke was shown [26]. It was suggested that GST-π could have an influence on cellular redox status through the suppression of the production of superoxide anions and peroxides [26].

Closely associated with the inflammatory process are free radicals [11]. Pro/antioxidative imbalance induced by smoke xenobiotics is involved in the pathogenesis of among others acute pancreatitis [6,27]. It was also shown that oxidative conditions can exert changes in the lipid profile in the blood and impair HDL-associated antioxidant defense [28]. Our study was aimed to demonstrate the extent to which tobacco smoke exposure is associated with the changes in lipids through assessment of their blood concentrations in healthy volunteers and patients with AP exposed to tobacco smoke xenobiotics: the concentration of MDA, HNE-adducts with proteins, oxLDL, HDL, total cholesterol, the value of Castelli index 1. The study was also aimed to evaluate the concentration of PON-1 and its phosphotriesterase, arylesterase and lactonase activities as lipid-bound enzymes within the cell membrane. The activity of GST-π as an enzyme responsible for detoxification of smoke xenobiotics in the study population was also determined.

Materials and Methods

Materials

The study group consisted of 46 patients with the diagnosis of AP (22 non-smokers and 24 smokers),
hospitalized in the Second Clinic of General and Oncological Surgery of Wroclaw Medical University Hospital in years 2014–2016 and 95 healthy volunteers (72 non-smokers and 23 smokers). The study protocol was approved by Local Bioethics Committee of Wroclaw University of Medicine (No: KB-592/2013). The study inclusion criteria are presented in Figure 1.

The volunteers were included based on the research conducted by primary care physicians. Exclusion criteria from the study group were as follows: presence of co-morbidities, such as neoplastic disease, diabetes, liver disease, ongoing inflammatory states other than AP as well as present or past alcohol and drugs abuse. To confirm the lack of alcohol abuse, carbohydrate-deficient transferrin (CDT) (CEofix CDT kit for Beckman Coulter P/AE MDQ Series; Ref. No.: 84411036), a biomarker for long-term alcohol consumption, was measured.

---

**Figure 1.** Criteria for the inclusion the patients to the study.
All hospitalized patients and healthy volunteers had received full and thorough information about the study and gave the informed consent in writing. Lifestyle data were gathered in the form of a medical interview and survey. Participants were asked about their health and nutritional habits, use of dietary supplements/medications, frequency of alcohol intake and smoking history. Smoking status was categorized as non-smokers and smokers based on the interview, but it was also verified by determination of serum cotinine concentrations, a metabolite of nicotine. Patients and healthy subjects were considered smokers when cotinine concentration was greater or equal than 15 ng/ml and non-smokers when cotinine concentration was lesser than 15 ng/ml; The interview acquired data on the intensity of smoking (assuming 20 cigarettes in a pack). Body mass index (BMI) was calculated as weight [kg]/(height [m])². Clinical characteristics of the study population were presented in Table 1.

Sample preparation

The biochemical analyses were performed in serum, plasma and erythrocyte lysate collected from patients with AP and healthy volunteers. Venous blood was collected in the morning, after 12-h fasting. The blood samples from hospitalized patients were collected on their 1st, 3rd and 7th day of treatment. Serum was obtained according to the standard procedure by taking venous blood for disposable trace-element-free tubes (Cat. No.: 368815, Becton Dickinson, Germany) with serum clotting activator, left at 25°C to complete thrombosis, and centrifuged (1200g/20 min). In order to obtain plasma and erythrocyte lysate, whole blood was drawn into tubes containing heparin (Cat. No.: 368866, Becton Dickinson, Germany) and centrifuged (2,500g/15 min) to separate the plasma and buffy coat from erythrocyte pellet. The erythrocytes were then directly transferred to other tubes to prevent hemolysis. The erythrocyte pellet was washed twice in an equal volume of ice-cold 0.9% NaCl. The washed cells were lysed by addition of ice-cold double distilled water (1:1.4). The resulting lysate was used for the assays. The obtained samples of serum, plasma and erythrocyte lysate were portioned and stored in sealed tubes (Cat. No.: 0030102.002, Eppendorf, Germany). The samples were stored at -80°C until analysis.

Methods

Cotinine concentration in serum was measured with the use of commercial Cotinine ELISA test (Cat. No.: ELA-3242, DRG International, Inc., USA). It provides qualitative screening results for cotinine in human serum at a cut-off concentration of 15 ng/mL.

High-sensitivity CRP (hsCRP) concentration was determined in serum by turbidimetric method using C-reactive protein hs test (Cat. No.: 31927, Biosystems, Spain).

Table 1. Clinical characteristics of the participants in the study.

| Parameters                  | Non-smokers Mean ± SD | Smokers Mean ± SD |
|-----------------------------|-----------------------|-------------------|
| Healthy subjects            |                       |                   |
| Age [years]                 | 24.3 ± 5.4            | 23.4 ± 2.4        |
| BMI [kg/m²]                 | 22.2 ± 2.8            | 22.6 ± 3.0        |
| hsCRP [mg/l]                | 0.2 ± 0.1             | 3.3 ± 2.8         |
| Pack years of smoking       | NA                    | 3.5 ± 2.6         |
| Cotinine [ng/ml]            | 1.6 ± 2.1             | 79.5 ± 40.1       |
| Patients with AP            |                       |                   |
| Age [years]                 | 50.0 ± 19.5           | 45.8 ± 13.1       |
| BMI [kg/m²]                 | 27.3 ± 4.7            | 23.9 ± 4.2        |
| The number of AP attacks in the past | 1-3 | 2-10 |
| Ranson Criteria [score]     | 2.5 ± 0.9             | 2.5 ± 0.7         |
| hsCRP [mg/l]                | 167.7 ± 54.1          | 136.5 ± 74.8      |
| Leukocytes [10⁹/l]          | 11.3 ± 4.7            | 9.8 ± 5.3         |
| Erythrocytes [10⁹/l]        | 4.1±0.9               | 4.0 ± 0.7         |
| Hemoglobin [g/dl]           | 12.2 ± 2.4            | 11.9 ± 1.9        |
| Hematocrit [%]              | 36.4 ± 6.2            | 35.4 ± 4.4        |
| Bilirubin (total) [mg/dl]   | 0.9 ± 0.6             | 1.2 ± 0.6         |
| ALAT [U/l]                  | 23.4 ± 17.5           | 37.3 ± 35.1       |
| ASPAT [U/l]                 | 30.9 ± 15.7           | 38.6 ± 27.2       |
| Alkaline phosphatase [U/l]  | 143.3 ± 104.4         | 135.1 ± 75.3      |
| Lipase [U/l]                | 465.7 ± 668.5         | 355.8 ± 476.1     |
| Glucose [mg/dl]             | 104.5 ± 22.9          | 116.8 ± 27.2      |
| Urea [mg/dl]                | 18.3 ± 8.9            | 294.7 ± 179.9     |
| Creatinine [mg/dl]          | 1.0 ± 0.8             | 1.4 ± 1.7         |
| Pack years of smoking       | NA                    | 23.0 ± 18.6       |
| Cotinine [ng/ml]            | 0.9 ± 0.8             | 142.5 ± 48.9      |

NA: not applicable

1) p<0.05 compared to non-smoking healthy subjects
2) p<0.05 compared to smoking healthy subjects
3) p<0.05 compared to non-smoking AP patients

MDA concentration in plasma was determined by colorimetric method using Lipid Peroxidation (MDA) Assay Kit (Cat. No.: MAK085-1KT, Sigma-Aldrich, Germany).

HNE-adducts concentration in serum was measured with the use of commercial test OxiSelect HNE Adduct Competitive ELISA Kit (Cat. No.: STA-838, Cell Biolabs, USA).

To determinate the level of oxLDL in serum, the commercial Mercodia Oxidised LDL ELISA kit was used (Cat.: No.: 10-1143-01, Mercodia, Sweden).

HDL concentration in serum was determined using a direct method with the commercial test (Cat. No.: 10300060, BioMaxima, Poland). HDL was subjected to enzymatic reaction which resulted in the formation of color compounds. The amount of color
product was proportional to the HDL concentration in the sample. The absorbance was measured at λ=600 nm at 25°C.

Total cholesterol (CH total) in serum was measured using a reagent for the quantitative determination of total cholesterol (Cat. No.: 5017.1; BioMaxima, Poland). Cholesterol was measured enzymatically according to the procedure described in technical bulletin provided by the manufacturer. The color intensity was proportional to cholesterol concentration. Absorbance was measured at λ=500 nm at 25°C.

The ratio CH total concentration/HDL concentration was expressed as Castelli Index 1 [29].

Phosphotriesterase activity of PON-1 (PON-1(P)) was measured in fresh serum according to the spectrophotometric method described by Bizzoni et al. [18]. The method utilizes the ability of PON-1 to split ester linkages in paraoxon at 37°C in a 100 mM Tris-HCl buffer (pH 8.5) containing 2 mM CaCl₂. As a result, p-nitrophenol is formed, the amount of which is proportional to the change in absorbance over time at λ=405 nm. The amount of 4-nitrophenol produced was then calculated from the molar extinction coefficient of 18.053 (μmol/L)−1 cm−1. One unit of PON-1(P) activity was expressed as 1 μmol of paraoxon hydrolyzed per minute at a temperature of 37°C.

Arylesterase activity of PON-1 (PON-1(A)) was determined in fresh serum by the process described earlier by Eckerson et al. [30] and Lixandru et al. [31] with own modifications. The method utilises phenyl acetate (Cat. No.: 122-79-2; Sigma-Aldrich, Germany) as a substrate at 37°C in a 20 mM Tris-HCl buffer (pH 8.0) containing 1 mM CaCl₂. As the effect of phenyl acetate hydrolysis, phenol was formed, what resulted in a change in absorbance over time at λ=270 nm. The amount of produced phenol was calculated from the molar extinction coefficient of 1310 (mol/L)−1 cm−1. One unit of PON-1(A) activity was expressed as 1 μmol of phenol acetate hydrolyzed per minute at a temperature of 37°C.

Lactonase activity of PON-1 (PON-1(L)) was determined in fresh serum by modified method described previously by Kataoka et al. [32]. The method uses dihydrocoumarin (Cat. No.: 119-84-6; Sigma-Aldrich, Germany) as a substrate at 37°C in a 50 mM Tris-HCl buffer (pH 7.0) containing 1 mM CaCl₂. As the effect of dihydrocoumarin hydrolysis, 3-(2-hydroxyphenyl)propionate was formed, which resulted in a change in absorbance over time at λ=270 nm. The amount of produced 3-(2-hydroxyphenyl) propionate was calculated from the molar extinction coefficient of 1870 (mol/L)−1 cm−1. One unit of PON-1(L) activity was expressed as 1 μmol of dihydrocoumarin hydrolyzed per minute at a temperature of 37°C.

The changes in absorbance for PON-1 activities (PON-1(P), PON-1(A) and PON-1(L)) were measured at 10 s intervals for 1-3 min.

The concentration of PON-1 was measured in serum using Paraoxonase 1 Human ELISA kit (Cat. No.: RD191279200R, BioVendor, Czech Republic).

GST-π activity in erythrocyte lysate was measured spectrophotometrically using ethacrynic acid (0.2 mM) in ethanol as substrate, according to Habig et al. [33]. The assay was conducted at 25°C in 100 mM potassium phosphate at pH=6.5 and 5 mM GSH concentration. The change in absorbance was measured at λ=270 nm. One unit of enzyme activity was defined as amount of enzyme catalyzing the conversion of 1 μmole of substrate per minute at 25°C. The results of GST-π activity were expressed as U/g hemoglobin.

Hemoglobin concentration in the erythrocyte lysate was measured using Drabkin reagent (Cat. No.: 20082, Aqua-Med, Poland).

The absorbance of samples was measured using a spectrophotometers: Specord 40 (Analytic Jena, DE, Cat. No.: 400280), MultiScan Go (Thermo Scientific, USA, Cat. No.: N10588) and Genesys 10S (Thermo Scientific, USA, Cat. No.: 840-208100).

Statistical analysis

The data was expressed as mean ± standard deviation (SD) values. The differences between the examined groups were tested using a 2-way Analysis of Variance (ANOVA) with Tukey’s multiple comparison test (the activities of PON-1(P), PON-1(A) and PON-1(L), GST-π, the concentrations of hsCRP, oxLDL, CH, HDL, PON-1) or a nonparametric Kruskal-Wallis test (the concentrations of cotinine, MDA, HNE-adducts, the value of Castelli Index 1). The normality of the variables was analyzed with use of the Shapiro-Wilk W test. In order to verify correlations between examined parameters, the multiple linear regression models were performed. In all instances, p<0.05 was considered statistically significant. Statistical calculations were done using the Statistica Software Package, version 10.0 (Polish version: StatSoft, Krakow, Poland).

Results

The effect of tobacco smoke exposure on the concentrations of oxidative stress markers and the values of Castelli-I index

An increased HNE-adducts concentration in the blood of patients with AP was observed, especially in
the group of smokers (p=0.045), compared to healthy subjects. It was noted that the level of this parameter was gradually elevating during hospitalization of both, smoking and non-smoking AP patients, but the differences were not statistically significant (Table 2).

It was observed that MDA plasma concentration was significantly higher in smokers compared to non-smokers, in both the patients with AP (p=0.047) and the healthy subjects (p=0.041). Additionally, the concentration of this marker was twice as high in AP patients when compared to appropriate healthy subjects, with significant differences between smokers (p<0.001) and non-smokers (p<0.001), respectively. It was noted that MDA concentration gradually elevated during hospitalization. Values of this parameter in the non-smoking AP patients were significantly increased by more than 30% (p=0.020) and 40% (p=0.011) on the 3rd and 7th day of hospitalization respectively compared to the 1st day. In the group of AP patients who were smokers, blood MDA concentration was higher by 30% on the 7th day of hospitalization when compared to the 1st (p=0.006) and 3rd day (p=0.041) (Table 2).

A higher oxLDL levels in the blood of patients with AP compared to healthy subjects, in both non-smokers (p=0.028) and smokers (p=0.008), were noted. This parameter remained elevated during hospitalization of AP patients (Table 2).

Significant decreases in HDL concentrations in the blood of patients with AP compared to healthy subjects, in both smokers (p<0.001) and non-smokers (p<0.001) were observed. Additionally, changes in HDL concentrations during hospitalization of AP patients were shown. In the group of non-smoking patients with AP, HDL concentration was lower by half on the 7th day of hospitalization compared to the 1st day. Decreases by 50% in the HDL concentrations on the 3rd (p=0.036) and the 7th (p=0.024) day of hospitalization compared to day one in the blood of smoking patients with AP were shown (Table 2).

Table 2. The influence of tobacco smoke exposure to the dynamics of changes in the concentration of lipids peroxidation products (HNE-adducts, oxLDL, MDA) and the parameters of lipids metabolism (HDL, total cholesterol concentration, Castelli index 1) in the blood of patients with AP (in the 1st, 3rd and 7th day of hospitalization) and healthy subjects.

| Parameters                     | Patients with AP                  | Healthy subjects               |
|--------------------------------|-----------------------------------|--------------------------------|
|                                | Non-smokers (Mean ± SD)           | Smokers (Mean ± SD)            | Non-smokers (Mean ± SD) | Smokers (Mean ± SD) |
| HNE-adducts [μg/ml]            |                                  |                                |                          |                    |
| 1st day                        | 18.9 ± 8.9                        | 22.5 ± 15.1                   | 11.0 ± 9.0               | 10.7 ± 7.4          |
| 3rd day                        | 25.2 ± 14.3                       | 30.7 ± 13.9                   |                            |                    |
| 7th day                        | 37.0 ± 23.2                       | 39.5 ± 31.8                   |                            |                    |
| MDA [nmol/μl]                  |                                  |                                |                          |                    |
| 1st day                        | 2.0 ± 0.3                         | 2.5 ± 0.6                     | 1.1 ± 0.7                | 1.4 ± 0.7           |
| 3rd day                        | 2.8 ± 0.8                         | 2.6 ± 0.6                     |                            |                    |
| 7th day                        | 3.2 ± 1.1                         | 3.1 ± 0.5                     |                            |                    |
| oxLDL [U/l]                    |                                  |                                |                          |                    |
| 1st day                        | 87.7 ± 43.7                       | 97.0 ± 47.7                   | 52.6 ± 17.6              | 58.7 ± 19.3         |
| 3rd day                        | 106.5 ± 33.6                      | 101.4 ± 36.1                  |                            |                    |
| 7th day                        | 89.4 ± 55.6                       | 71.1 ± 22.4                   |                            |                    |
| HDL [mg/dl]                    |                                  |                                |                          |                    |
| 1st day                        | 20.7 ± 12.3                       | 22.4 ± 12.3                   | 50.9 ± 21.3              | 47.3 ± 7.0          |
| 3rd day                        | 14.0 ± 8.0                        | 13.2 ± 7.3                    |                            |                    |
| 7th day                        | 8.5 ± 6.3                         | 11.5 ± 4.4                    |                            |                    |
| CH total [mg/dl]               |                                  |                                |                          |                    |
| 1st day                        | 129.9 ± 36.4                      | 149.4 ± 43.3                  | 182.5 ± 37.4             | 176.1 ± 24.2        |
| 3rd day                        | 138.5 ± 32.0                      | 137.7 ± 23.5                  |                            |                    |
| 7th day                        | 126.7 ± 34.3                      | 138.7 ± 22.8                  |                            |                    |
| Castelli index 1               |                                  |                                |                          |                    |
| 1st day                        | 5.8 ± 2.0                         | 5.4 ± 2.6                     | 4.0 ± 1.9                | 4.2 ± 1.8           |
| 3rd day                        | 11.9 ± 7.1                        | 9.5 ± 7.0                     |                            |                    |
| 7th day                        | 16.1 ± 10.6                       | 14.1 ± 9.5                    |                            |                    |

1) p<0.05 compared to smoking healthy subjects. 2) p<0.05 compared to non-smoking healthy subjects. 3) p<0.05 compared to non-smoking AP patients. 4) p<0.05 compared to the 1st day of hospitalization. 5) p<0.05 compared to the 3rd day of hospitalization.
A decrease in total cholesterol (CH total) concentration in the blood of patients with AP compared to healthy subjects was observed. CH total concentration was lowered by 30% in the blood of non-smoking AP patients and by more than 20% in the blood of smoking AP patients compared to non-smokers (p<0.001) and smokers (p=0.015) of healthy subjects, respectively (Table 2).

Castelli Index 1 in the examined groups was calculated. An increased value of Castelli Index 1 in the group of non-smoking patients with AP compared to healthy non-smokers (p=0.013) was shown. It was shown that the values of this parameter were gradually increasing during hospitalization of both, non-smoking and smoking AP patients. Near 2-fold increase in the value of Castelli index 1 was observed on the 3rd day of hospitalization (p=0.035 and p=0.038 for non-smokers and smokers, respectively) and more than 2-fold increase on the 7th day of treatment, when compared to the 1st day (p=0.018 and p=0.001 for non-smokers and smokers, respectively) (Table 2).

**The effect of tobacco smoke exposure on the activities and concentration of PON-1 and GST-π activities**

The activity of PON-1(P) decreased nearly 2-fold in the blood of non-smoking patients with AP compared to healthy non-smokers (p=0.003). Additionally, a progressive decrease in the activity of this enzyme in the group of smoking patients with AP was observed. The activity of PON-1(P) in patients on the 7th day of treatment was nearly 2-fold lower compared to the one on the 1st day in this group (p=0.028). PON-1(P) was also decreased (by 30%) in healthy smokers compared to non-smokers (p=0.003) (Figure 2).
Significantly lower PON-1(A) activities in the blood of patients with AP compared to healthy subjects, in both smokers (p=0.031) and non-smokers (p=0.030) were observed. Additionally, it was observed that the activity of this enzyme was gradually decreasing during hospitalization of smoking AP patients (p=0.047 for comparison of the 1st and the 7th day) (Figure 2).

A decrease in the activity of PON-1(L) in the blood of AP patients compared to healthy subjects, in both non-smokers (p=0.001) and smokers (p<0.001) was shown. Additionally, it was observed that PON-1(L) activity was continually decreasing during hospitalization of smoking AP patients (p=0.024 for comparison of the 1st and the 3rd day of hospitalization and p=0.033 for comparison of the 1st and the 7th day of hospitalization) (Figure 2).

A decreased PON-1 concentration in the blood of AP patients, especially in smokers was shown compared to smoking healthy subjects (p=0.040). The level of this parameter remained unchanged during hospitalization of AP patients (Figure 2).

The analysis of PON-1 activities and the concentration of all subtypes with respect to age and BMI was presented in Figure 3. A decrease in the activities of PON-1(A) and PON-1(L) in the blood of AP patients and healthy was observed in subjects of age ≥40 as compared to those of age<40 (PON-1(A): p=0.033 in smoking AP patients; PON-1(L): p=0.049 and p=0.041 in non-smoking and smoking AP patients, respectively; p=0.018 for non-smoking healthy subjects). Similar differences with respect to age groups were noted in PON1 concentration (p=0.016 in non-smoking AP patients). There were no differences in PON-1 concentration and activity between individuals with BMI <25 kg/m² compared to those with BMI ≥25 kg/m² in both groups, patients with AP and healthy subjects (Figure 3).

The gradual increase in the activity of GST-π during hospitalization of non-smoking patients with AP was observed. It was shown that GST-π activity was higher on the 3rd and the 7th day compared to the 1st day of hospitalization (p=0.049 and p=0.022, respectively). A significant decrease in the activity of this enzyme in the smoking healthy subjects compared to healthy non-smokers was also observed (p=0.005) (Figure 4).

Correlation tests between examined parameters were performed. The obtained correlation coefficients between parameters measured in the blood of healthy subjects and patients with AP were presented in Table 3 and Table 4.

Table 3. The correlation coefficients resulted for linear regression performed between the activities of PON-1 and parameters determined in the blood of patients with AP and healthy subjects.

| Parameters       | PON-1(P) | PON-1(A) | PON-1(L) |
|------------------|----------|----------|----------|
| HDL              | r= 0.6326 | r= 0.7176 | NS       |
| p=0.050          | p= 0.045  |          |          |
| Castelli index 1 | NS       | NS       | r= - 0.8163 |
|                  |          |          | p= 0.048  |
| oxLDL            | NS       | r= - 0.8901 | p= 0.043  |
|                  |          |          | p= 0.032  |
| HNE-adducts      | r= - 0.9718 | r= - 0.9061 | p= 0.028  |
|                  | p= 0.008  | p= 0.034  | p= 0.016  |
| Smokers patients with AP |         |          |          |
| Age              | NS       | r= - 0.4927 | r= - 0.5246 |
|                  |          | p= 0.032  | p= 0.021  |
| HDL              | NS       | r= 0.4999 | NS       |
|                  |          | p= 0.025  |          |
| Castelli index 1 | NS       | NS       | r= - 0.5331 |
|                  |          |          | p= 0.025  |
| Cotinine         | NS       | r= - 0.4787 | r= - 0.5576 |
|                  |          | p= 0.033  | p= 0.008  |
| MDA              | r= - 0.6030 | r= - 0.4980 | p= 0.038  |
|                  | p= 0.001  | p= 0.035  | p= 0.017  |
| Smoking healthy subjects |         |          |          |
| MDA              | r= - 0.5290 | r= - 0.4845 | r= - 0.4823 |
|                  | p= 0.024  | p= 0.042  | p= 0.036  |

NS – not statistically significant.
HDL – high density lipoprotein; HNE-adducts – protein adducts of 8-hydroxynonenal; MDA – malonyldialdehyde; oxLDL – oxidized low density lipoproteins; PON-1(P) – phosphotriesterase activity of paraoxonase-1; PON-1(A) – arylesterase activity of paraoxonase-1; PON-1(L) – lactonase activity of paraoxonase-1.

Table 4. The correlation coefficients resulted for linear regression performed between oxidative stress markers and parameters determined in the blood of patients with AP and healthy subjects.

| Correlations | r   | p   |
|--------------|-----|-----|
| MDA – GST-π  | -0.9658 | p<0.001 |
| MDA – HDL    | -0.8920 | 0.042  |
| MDA – hsCRP  | 0.9031  | 0.014  |
| Castelli index 1 – hsCRP | 0.8978 | 0.015  |
| Castelli index 1 – Ranson score | 0.7549 | 0.030  |
| SMokers patients with AP |         |          |
| Age - PON-1 concentration | -0.7117 | 0.016  |
| Cotinine – MDA | 0.5764 | 0.012  |
| Cotinine – HDL | -0.5605 | 0.016  |
| MDA – HDL    | -0.6227 | 0.008  |
| MDA – Castelli index 1 | 0.5898 | 0.034  |
| HNE-adducts - hsCRP | -0.6332 | 0.049  |
| Non-smokers healthy subjects |        |          |
| oxLDL – Castelli 1 index | -0.6466 | 0.043  |
| Smoking healthy subjects |       |          |
| HNE adducts – CH total | -0.6962 | 0.002  |

CH total – total cholesterol; GST-π – P’ isomerase of glutathione S-transferase; HDL – high density lipoprotein; hsCRP – high sensitive C-reactive protein; MDA – malonyldialdehyde; HNE-adducts – protein adducts of 8-hydroxynonenal; oxLDL – oxidized low density lipoproteins.
Discussion

Oxidative stress implicated in the pathogenesis of acute pancreatitis can intensify the damage of pancreatic tissue [34]. Additionally, oxidative stress induced by the smoke can activate a pro-inflammatory cascade, what intensifies a preexisting inflammation [9]. Results of this study confirm that AP is associated with generation of strong oxidative stress, gradually increasing during hospitalization of the patients. It leads to intensified lipid peroxidation, what was reflected in elevated MDA concentration and the lack of normalization in HNE-adducts and oxLDL levels in the blood of both, smoking and non-smoking AP patients. These results confirm rather intuitive thesis that the course of AP is more potent inducer of oxidative stress in comparison to exposure to tobacco smoke xenobiotics.
Enhanced oxidative stress induced by smoking and inflammatory mechanisms of AP may interfere with membrane-linked antioxidants, such as PON-1 [35,36]. PON-1 associated with HDL molecule is able to hydrolyze hydrogen peroxide, which is a major form of reactive oxygen produced during oxidative stress [37]. On the other hand, studies conducted in vitro showed that this enzyme can be easily inactivated by hydroxyl radicals [38]. In our study, a decrease in PON-1(P), PON-1(A) and PON-1(L) activities in AP in comparison to healthy subjects was demonstrated, what is consistent with observations by other authors [11,28,39]. Simultaneous decrease in PON-1 activities, negatively correlating with levels of lipids peroxidation markers can indicate that lipid peroxidation products can affect PON-1 structure and inhibit its activity. Other research showed that lipids peroxidation products can form adducts with highly nucleophilic sulfhydryl thiolate groups on cysteine, lysine and histidine residues, what can modify reactivity of membrane proteins [40].

To explain pathomechanism of changes in PON-1 activities, the concentration PON-1, HDL and total cholesterol were determined. Reduced PON-1 activities in AP patients compared to healthy subjects, accompanied by decreased PON-1 concentration in smokers, can indicate disorders in hepatic synthesis of this enzyme in this group. Additionally, analysis of PON-1 concentrations/activities with respect to age and BMI, as factors that can affect PON-1 synthesis, showed an inverse relation of these parameters to age in the group of AP patients. It remains in accordance with the results of the study conducted by Kumar et al., in which a strong relation of age and PON-1 activity was shown [41]. It was noted that age was strongly related to the increase of blood level of lipid peroxidation markers, which could impair PON-1 function as antioxidant or its synthesis dependent on lipoprotein metabolism [41]. There is evidence that the PON-1 activity/concentration is an adjunctive marker of altered lipoprotein metabolism as protein affects the process of cholesterol efflux [41].

The changes in PON-1 concentration and activity can also be related to ongoing inflammatory process, what was confirmed by the difference demonstrated only in the group of AP patients, in contrast to healthy subjects. A decrease in PON-1 activity may be secondary to increased levels of pro-inflammatory cytokines, which are responsible for downregulation of mRNA expression of PON-1, as it was demonstrated in earlier studies [42,43]. The pathomechanism of reduced PON-1 activities can be also associated with lipid metabolism disorders in AP, what reflects particularly in HDL fraction [28,44]. Other researchers noted that inflammation and acute phase response are associated with a lower rate of lipoprotein synthesis in the liver [45]. In our study, increasing Castelli Index 1 during hospitalization of AP patients could be a result of disorders in HDL synthesis or low fat supply in diet, what also induced the decreased PON-1 activity. It was evidenced by negative correlation of Castelli Index 1 with PON-1 activity showed in the groups of non-smoking and smoking AP patients. A decrease in PON-1 activities can be a result of HDL dissociation from PON-1 molecule, its oxidation and increase in lipid peroxidation products concentrations under oxidative stress conditions as reported in other papers [46,47]. This thesis seems to be confirmed in our study by the strong correlations of PON-1 activities with HDL concentration and negative association of HDL and MDA concentrations in the groups of AP patients. Additionally, oxidative stress generated in the course of AP can be associated with escalation of
inflammation, what was confirmed by the correlation of MDA or HNE-adducts with hsCRP concentrations showed in the group of non-smoking and smoking AP patients. It seems reasonable to search for reduction of this prooxidative and pro-inflammatory cascade by inclusion in the therapy medications with anti-inflammatory properties.

The results of this study showed the effect of smoking on PON-1 activities. Exposure to tobacco smoke xenobiotics was associated with the highest decrease in PON-1(P) activity, which most strongly correlated with MDA concentration in smokers. This result can indicate that PON-1(P) activity revealed high sensitivity to smoke xenobiotics as compared to the activity of other of the enzyme forms, what manifested in its inhibited activity in healthy smokers without accompanied decrease in PON-1 concentration. This effect can be explained by the interaction of reactive tobacco smoke xenobiotics (aldehydes, polycyclic aromatic hydrocarbons or heavy metals) with active center of PON-1 causing steric hindrance near region of the molecule critical for substrate binding, modification of thiol groups in active regions of PON-1 and inactivation of the entire enzyme [44,48–50].

A decreased activity of PON-1 in the course of AP is considered a marker of oxidative damage (11). Destruction of cell membrane and extracellular antioxidant defense activation can lead to disruption of the intracellular redox homeostasis, what was confirmed in this study by a decrease in GST-π activity as a result of tobaccos smoke exposure. Down-regulation of GST-π activity may be caused by blocking of the active center of the enzyme by smoke xenobiotics or the enzyme use up in detoxification processes. Sen et al. [51] showed that GST-π activity can be reduced by Cd, which intake into organism is mainly associated with tobacco smoke exposure. These findings were consistent with our study, in which the decrease in GST-π activity was strongly correlated with the increased Cd concentration in the blood of healthy smokers. GST-π free radical scavenging potential seems to be weakened by oxidative stress produced in the course of AP, what was confirmed by negative correlation of this enzyme activity and MDA concentration in the blood of non-smoking AP.

Conclusions
- Increasing stay in the hospital was associated with worsening of lipids peroxidation markers and the parameters of lipid profile, in both non-smoking and smoking AP patients. It can indicate that the oxidative-inflammatory process is not extinguished.
- Oxidative stress generated in the course of AP can intensify the preexisting inflammation.
- The intensification of lipid peroxidation and damage of cellular membrane may be associated with a decrease in PON-1 activities into the blood of AP patients as a result of oxidative modification of HDL - an important molecule in proper PON-1 function.
- A decrease in PON-1 phosphotriesterase activity observed in smoking AP patients is an effect of the enzyme activity inhibition, rather than a decrease in PON-1 concentration. Inhibition of GST-π activity can be a result of the interference of tobacco smoke xenobiotics with active center of this enzyme.

Abbreviations
AP: acute pancreatitis; CH: total cholesterol; GST-π: pi isoform of glutathione S-transferase; HDL: high density lipoproteins; HNE: hydroxynonenal; hsCRP: high-sensitivity C-reactive protein; MDA: malonyldialdehyde; oxiLDL: oxidized low density lipoproteins; PON-1: paraoxonase-1; PON-1(A): arylesterase activity of paraoxonase-1; PON-1(L): lactonase activity of paraoxonase-1; PON-1(P): phosphotriesterase activity of paraoxonase-1.

Acknowledgements
This work was supported by the grant ST.D170.16.014 and STM.D170.17.006 from Wroclaw Medical University.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Jamer T. Etiology of acute pancreatitis - underestimated problem in pediatrics. Dev Period Med. 2015; 3:341-6.
2. Kylander L, Rakonczay Z, O'Reilly DA. The clinical course of acute pancreatitis and the inflammatory mediators that drive it. Int J Inflamm. 2012; 2012:1–10.
3. Bhatia M, Brady M, Shokhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol. 2000;190:117–25.
4. Yu JH. Oxidative stress and inflammatory signaling in cerulein pancreatitis. World J Gastroenterol. 2014; 20:17324.
5. Kumar R, Bhatia M. Cells and mediators of inflammation in acute pancreatitis. Clin Anti-Inflam Anti-Allergy Drugs. 2014; 1:1–23.
6. Barreto SG. How does cigarette smoking cause acute pancreatitis? Pancreatology. 2016; 16:157-63.
7. Edderkoussi M, Throver E. Smoking and pancreatic disease. J Cancer Ther. 2013; 4:34–40.
8. Milnerowicz H, Ściskalska M, Dul M. Molecular mechanisms of the impact of smoke-oxidants. Exp Toxicol Pathol. 2015; 67:377–82.
9. Milnerowicz H, Ściskalska M, Dul M. Pro-inflammatory effects of metals in persons and animals exposed to tobacco smoke. J Trace Elem Med Biol. 2015; 29:1–10.
10. Levitzky YS, Guo C-Y, Rong J, Larson MG, Walter RE, Keaney JF, et al. Relation of smoking status to a panel of inflammatory markers: The Framingham offspring. Atherosclerosis. 2008; 201:217–24.
11. Tvarijonaviciute A, Garcia-Martinez JD, Caltin M, Martinez-Subiela S, Tecles F, Pastor J, et al. Serum paraoxonase 1 (PON1) activity in acute pancreatitis of dogs. J Small Anim Pract. 2015; 56:67–71.
12. van der Vaart H, Postma DS, Timens W, ten Hacken NHT. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax. 2004; 59:713-21.

13. Agirbasli LS, Pharmacology of free radicals and the impact of reactive oxygen species on the testis. J Reprod Infantil. 2013; 14:158-172.

14. V Ramana K. What is the role of lipid peroxidation product 2-hydroxynonenal in inflammation? Biochem Anal Biochem [Internet]. 2012. Revised 2012 Mar 15. https://www.omicsonline.org/what-is-the-role-of-lipid-peroxidation-product-2-hydroxynonenal-in-inflammation-2161-1005.1001e105.php?aid=659 9.

15. Novak F, Vavraova I, Kodykova J, Novak F, Hynkova M, Zak A, et al. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med. 2010; 10:21-5.

16. Ashlan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol Arch Med Wewn. 2011; 121:181-6.

17. Mehdi MM, Rizvi SL. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation. Arch Med Res. 2012; 43:438-43.

18. Bizon A, Kepinska M, Snacki K, Milnerowicz H. The impact of environmental and biological factors on paraoxonase 1 and γ-glutamyltransferase activities in the blood of smokers. Int J Environ Health Res. 2016; 26:222-38.

19. Krzyzew-Korpacka M, Patryn E, Hotowy K, Czapińska E, Majda J, Kustrzeba-Wojcicka I, et al. Paraoxonase (PON1) enzyme activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med. 2013; 22:229-36.

20. Zhou C, Cao J, Shang L, Tong C, Hu H, Wang H, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. DisMarkers. 2013; 35:97-103.

21. Ferretti G, Bacchetti T, Miascangolo S, Bicchiagia V. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity. 2010; 18:1079-84.

22. Ceron JJ, Cardenas F, Travijonaviciute A. Serum paraoxonase 1 (PON1) measurement: an update. BMC Vet Res. 2014; 10:74.

23. Erdem FH, Karatay S, Yildirim K, Kiziltunc A. Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients. Clinics. 2010; 65:175-9.

24. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J. 2001; 354:1-7.

25. Conklin DJ, Habezeitl P, Prough RA, Bhatnagar A. Glutathione S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke. Am J Physiol Heart Circ Physiol. 2009; 296:H1586-1597.

26. Aliya S, Reddanna F, Thiyagaraju K. Does glutathione S-transferase P (GST-P) play a role in tobacco? Indian J Med Res. 2010; 130:175-9.

27. Rau B. Pathophysiologic role of oxygen free radicals in acute pancreatitis. Ann Surg, 2000; 231:352-60.

28. Ural E, Uzun H, Kussaslan R, Dogan M, Genc H, Gunes P, et al. Serum paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity and lipid profile in experimental acute pancreatitis. Pancreas. 2005; 31:84-7.

29. Vargas HO, Nunes SOV, Barbosa DS, Vargas MM, Cestari A, Dodda S, et al. Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Am J Hum Genet. 1983; 53:214-27.

30. Kataoka M, Honda K, Shimizu S. 3,4-Dihydrocoumarin hydrolyse with haloperoxidase activity from Acinetobacter calcoaceticus F46. Eur J Biochem. 2008; 265:327-30.

31. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974; 249:7130-9.

32. Armstrong JA, Cash N, Soares PMG, Souza MHLP, Sutton R, Criddle DN. Oxidative stress in acute pancreatitis: lost in translation? Free Radic Res. 2013; 47:917-33.

33. Huang Y, Wu Z, Riwanot M, Gao S, Levison BS, Gu X, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013; 123:3815-28.

34. Sztanke F, Seres I, Harangi M, Loscey L, Padra J, Paragh GJ, et al. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant. 2012; 27:2866-72.

35. Aviram M, Rosenblat M, Biggai CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998; 101:1281-90.

36. Nguyen SD, Sok D-E. Oxidative inactivation of paraoxonase, an antioxidant protein and its effect on antioxidant action. Free Radic Res. 2003; 37:1319-30.